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Abstract
Most live-attenuated tetravalent dengue virus vaccines in current clinical trials are produced from Vero cells. In a previous
study we demonstrated that an infectious cDNA clone-derived dengue type 4 (DEN-4) virus retains higher genetic stability
in MRC-5 cells than in Vero cells. For this study we investigated two DEN-4 viruses: the infectious cDNA clone-derived DEN-4
2A and its derived 39 NCR 30-nucleotide deletion mutant DEN-4 2AD30, a vaccine candidate. Mutations in the C-prM-E,
NS2B-NS3, and NS4B-NS5 regions of the DEN genome were sequenced and compared following cell passages in Vero and
MRC-5 cells. Our results indicate stronger genetic stability in both viruses following MRC-5 cell passages, leading to
significantly lower RNA polymerase error rates when the DEN-4 virus is used for genome replication. Although no significant
increases in virus titers were observed following cell passages, DEN-4 2A and DEN-4 2AD30 virus titers following Vero cell
passages were 17-fold to 25-fold higher than titers following MRC-5 cell passages. Neurovirulence for DEN-4 2A and DEN-4
2AD30 viruses increased significantly following passages in Vero cells compared to passages in MRC-5 cells. In addition,
more severe DEN-induced hemorrhaging in mice was noted following DEN-4 2A and DEN-4 2AD30 passages in Vero cells
compared to passages in MRC-5 cells. Target mutagenesis performed on the DEN-4 2A infectious clone indicated that single
point mutation of E-Q438H, E-V463L, NS2B-Q78H, and NS2B-A113T imperatively increased mouse hemorrhaging severity. The
relationship between amino acid mutations acquired during Vero cell passage and enhanced DEN-induced hemorrhages in
mice may be important for understanding DHF pathogenesis, as well as for the development of live-attenuated dengue
vaccines. Taken together, the genetic stability, virus yield, and DEN-induced hemorrhaging all require further investigation
in the context of live-attenuated DEN vaccine development.
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Introduction
The four dengue serotype viruses DEN-1 to DEN-4 (genus
Flavivirus, family Flaviviridae) are single stranded, positive-sense
RNA viruses transmitted to humans primarily by Aedes aegypti
mosquitoes [1]. Their shared RNA genome contains coding
sequences for three structural protein genes (core C, precursor
membrane prM, and envelope E), seven non-structural protein
genes (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5), and two
flanking non-translating regions (NTRs) [2]. DEN infections in
humans result in illnesses ranging from dengue fever (DF) to
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS). Approximately 50–100 million infections occur annually,
including 500,000 cases of DHF and DSS [3,4,5,6,7]. DEN is
endemic in Southeast Asia, where severe forms of DHF and DSS
have become major causes of hospitalization among young
children [8]. Increases in DEN-related diseases in the past two
decades are likely the result of growing human populations, rapid
urbanization, the effects of global warming on mosquito vector
control, and expanded international travel [9].
There is an urgent need for a safe and effective dengue vaccine. A
live-attenuated DEN vaccine would deliver a complete set of
protective antigens to achieve long-lasting immunity [7]. The use of
live-attenuated tetravalent DEN vaccines against each of the four
serotypes would have the potential of minimizing the risk of severe
DEN-related diseases [7,10,11,12,13,14,15]. Wild type DEN strains
1 through 4 have been attenuated by serial passages in primary dog
and monkey kidney cells [10,13,14], and bulk vaccines have been
produced using diploid fetal rhesus monkey lung cells (FRhL) or
aneuploid African green monkey kidney epithelial cells (Vero)
[12,16,17]. Results from several clinical trials indicate that each
monovalent DEN vaccine is both immunogenic and safe [12,17].
However, tetravalent vaccine formulation trials have not resulted in
predicted responses, with immune imbalance or reactogenicity
occurring for certain DEN serotypes [13,14]. Although an attempt
has not been made for production of DEN vaccines, human diploid
MRC-5 cells have been used for the production of several live-virus
vaccines such as oral polio, rubella, small pox, and varicella zoster
[18]. Other vaccine developers have applied cDNA cloning via
chimeric virus technology and strategic modifications to generate
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DEN-4 with a deletion in 39 NTR, attenuated 17D yellow fever
vaccine, and DEN-2 strain PDK-53 [7,19,20,21,22,23,24,25,
26,27,28,29,30]. All of these cDNA-derived candidate vaccines
have been produced using Vero cells.
Passages of DEN viruses or their derived chimeras in Vero cells
generate mutations that are specific in terms of host cell
adaptation, virus attenuation, or other properties [31,32]. When
spot-checking sequences during chimeric DEN-2 PDK-53 vaccine
component manufacturing, Stinchcomb et al. (2007) observed the
loss of attenuating mutation markers in a number of seed stocks
during initial passages in Vero cells; these vaccine seeds were
rejected for further use [33]. It is possible that virus passage in
certain cells produce host cell-specific mutations that contribute to
innate immunity response in vaccinees.
We previously demonstrated that the infectious cDNA clone-
derived DEN-4 2A virus retains higher genetic stability in MRC-5
cells compared to Vero cells [34]. For the present study we
investigated the effects of serial passages in Vero cells and MRC-5
cells on two DEN-4 viruses: a recombinant version of wild type
virus DEN-4 2A, and its derived 39 NCR 30-nucleotide deletion
mutant vaccine candidate DEN-4 2AD30 [21,35]. DEN-4 2A and
DEN-4 2AD30 viruses were generated in Vero and MRC-5 cells
via the transfection of in vitro RNA transcripts synthesized using
SP6 RNA polymerase (Fig. 1A). For purposes of analyzing genetic
mutations that occur during cell passages, we collected ten plaque-
purified clones following passages P4 and P10 and sequenced the
DEN genomic fragments C-prM-E, NS2B-NS3 and NS4B-NS5
(Fig. 1B), since most mutations described in previous reports
occurred in those regions [34].
In addition to focusing on the genetic stability of DEN-4 2A and
DEN-4 2AD30 viruses following passages in Vero and MRC-5
cells, we also studied associated neurovirulence, neutralizing
antibodies, and DEN-induced hemorrhaging in mice. Specifically,
DEN neurovirulence attenuation was evaluated in newborn mice
and DEN-induced hemorrhaging was examined in an immuno-
competent mouse model [36,37]. Target mutagenesis on DEN4-
2A virus E and NS2B proteins were used to confirm the amino
acid mutations correlated with mouse hemorrhaging severity. We
found additional evidence indicating that (a) the genetic stability of
live-attenuated DEN candidate vaccine viruses varies according to
the cell line used for vaccine production, and (b) DEN-induced
hemorrhaging was much more severe following passages in Vero
cells compared to passages in MRC-5 cells.
Results
C-prM-E gene mutations resulting from Vero and MRC-5
cell passages
Mutations in the C-prM-E genes of DEN-4 2A viruses resulting
from passages in Vero and MRC-5 cells are shown in Table 1. We
found 7 nucleotide mutations in the C and E genes following Vero
cell passage P4, resulting in 1 amino acid mutation in the C protein
(C-F37L) and 5 in the E protein (E-R99K, E-T138P, E-G427R, E-
V439F, E-V463L). For viruses obtained following Vero cell passage
P10, we found 8 nucleotide mutations in the DEN-4 2A viruses of C-
prM-E genes, resulting in 1 amino acid mutation in the C protein (C-
F37L) and 6 in the E protein (E-R99K, E-T138P, E-G328S, E-G427R,
E-Q438H, and E-V463L). Amino acid mutations at E-G328Sa n dE -
Q438H were only detected following P10, with respective mutation
Figure 1. Experiment design. (A) Preparatory passages were performed for 10 cloned DNA-derived DEN-4 2A and 2AD30 strain virus plaque-
purified clones. Both strains were passaged 10 times each in Vero and MRC-5 cell lines. Virus clones were prepared from discontiguous passages P4
and P10. (B) The dengue virus genome and the sequenced gene fragments C-prM-E, NS2B-NS3 and NS4B-NS5 were used in this study.
doi:10.1371/journal.pone.0025800.g001
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E-V439F was only detected following Vero cell passage P4. In
contrast, following DEN-4 2A passage P4 in MRC-5 cells we found 3
nucleotide mutations in C-prM-E genes (corresponding to aminoacid
changes E-E345K, E-N362K, and E-G427R), and 3 mutations
following passage P10 (E-E345K, E-N362K, and E-Q438H).
Whereas no C-prM-E gene mutations were identified from
DEN-4 2AD30 sequencing following Vero cell passage P4
(Table 1), 4 (indicating 5 nucleotide changes) were identified
following passage P10 (E-R410G, E-V443A, E-T468K, and E-
T491P). No C-prM-E mutations for the DEN-4 2AD30 virus were
found following MRC-5 cell passages P4 or P10 (Table 1). The
reduced number of DEN-4 2AD30 virus mutations yielded only 4
amino acid changes following Vero cell passage P10; no DEN-4
2AD30 virus mutations were found following Vero cell passage P4
or MRC-5 cell passages P4 and P10.
NS2B-NS3 and NS4B-NS5 gene mutations during Vero
and MRC-5 cell passages
DEN-4 2A virus mutations in full-length NS2B-NS3 and NS4B-
NS5 genes are shown in Table 2. The P4 Vero cell passage of the
DEN-4 2A virus produced only 1 nucleotide change in NS2B-NS3
genes (amino acid mutation NS3-R418T); in contrast, 5 nucleotide
changes in NS2B-NS3 genes resulted from Vero cell passage P10 of
the same virus (mutations NS2B-G69R, NS2B-Q78H, NS2B-G108R,
NS2B-A113T, and NS3-R418T). For the DEN-4 2A virus, no
nucleotide mutations were found following MRC-5 cell passages P4
or P10 (Table 2); furthermore, no nucleotide mutations were
observed in NS4B-NS5 genes following DEN-4 2A virus passages
P4 or P10 in either Vero or MRC-5 cells (Table 2).
For DEN-4 2AD30, Vero cell passage P4 did not produce any
sequence mutations in NS2B-NS3 genes, but mutations at NS2B-
P31T, NS2B-E54D, NS2B-S71R, NS2B-E75Q, and NS2B-V76 M
were noted following P10 (mutation frequencies 100%, 100%,
30%, 100%, and 60%, respectively) (Table 2). No nucleotide or
amino acid mutations were observed in the NS3 gene of the DEN-
42 A D30 virus following Vero cell passage P10, nor in NS2B-NS3
genes following MRC-5 cell passage P4 or P10 (Table 2). Finally,
results from sequencing the NS4B-NS5 region indicate no
nucleotide mutations for either DEN-4 2A or DEN-4 2AD30
following Vero or MRC-5 cell passages.
DEN-4 2A and DEN-4 2AD30 virus titers following Vero
and MRC-5 cell passages
We also investigated the effects of Vero and MRC-5 cell
passages on DEN-4 2A and DEN-2AD30 virus growth. Virus titer
Table 1. Nucleotide (nt) and amino acid (aa) changes in C-prM-E fragments from plaque-purified Vero- and MRC-5-passaged DNA-
derived DEN-4 2A and DEN-4 2AD30 virus clones.
Virus Cell Passage Number Virus Gene Segment Mutation
Frequency
Plaque-purified
Clone Number
Nucleotide
Position
Amino Acid
Position
DEN-4 2A Vero 4 C 2/10 1, 8 T 210 C F 37 L
DEN-4 2A Vero 4 E 4/10 1, 3, 5, 8 G 296 A R 99 K
DEN-4 2A Vero 4 E 2/10 4, 9 A 412 C T 138 P
DEN-4 2A Vero 4 E 7/10 1, 2, 3, 6, 7, 9, 10 T 1050 A Silent
DEN-4 2A Vero 4 E 3/10 4, 8, 10 G 1279 C G 427 R
DEN-4 2A Vero 4 E 1/10 9 G 1315 T V 439 F
DEN-4 2A Vero 4 E 3/10 2, 5, 7 G 1387 T V 463 L
DEN-4 2A Vero 10 C 3/10 1, 3, 8 T 210 C F 37 L
DEN-4 2A Vero 10 E 10/10 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 G 296 A R 99 K
DEN-4 2A Vero 10 E 8/10 2, 3, 4, 5, 7, 8, 9,10 A 412 C T 138 P
DEN-4 2A Vero 10 E 5/10 3, 4, 7, 8, 9 G 982 A G 328 S
DEN-4 2A Vero 10 E 8/10 1, 2, 3, 5, 6, 7, 9, 10 T 1050 A Silent
DEN-4 2A Vero 10 E 5/10 2, 4, 5, 8, 10 G 1279 C G 427 R
DEN-4 2A Vero 10 E 10/10 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 G 1314 T Q 438 H
DEN-4 2A Vero 10 E 9/10 1, 2, 3, 5, 6, 7, 8, 9, 10 G 1387 T V 463 L
DEN-4 2A MRC-5 4 E 9/10 1, 2, 3, 4, 5, , 7, 8, 9, 10 G 1033 A E 345 K
DEN-4 2A MRC-5 4 E 4/10 2, 5, 8, 10 C 1086 A N 362 K
DEN-4 2A MRC-5 4 E 2/10 3, 7 G 1279 A G 427 R
DEN-4 2A MRC-5 10 E 10/10 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 G 1033 A E 345 K
DEN-4 2A MRC-5 10 E 3/10 5, 8, 10 C 1086 A N 362 K
DEN-4 2A MRC-5 10 E 1/10 3 G 1314 C Q 438 H
DEN-4 2AD30 Vero 10 E 2/10 1, 8 C 2169 G R 410 G
DEN-4 2AD30 Vero 10 E 8/10 1, 2, 5, 6, 7, 8, 9, 10 T 2231A Silent
DEN-4 2AD30 Vero 10 E 2/10 1, 8 T 2266 C V 443 A
DEN-4 2AD30 Vero 10 E 7/10 1, 2, 6, 7, 8, 9, 10 C 2341 A T 468 K
DEN-4 2AD30 Vero 10 E 4/10 1, 5, 7, 8 A 2370 C T 491 P
doi:10.1371/journal.pone.0025800.t001
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following P4 and P10 passages in both cell types are shown in
Figures 2A and 2B. The data indicate cell growth following DEN
virus infection at a MOI of 0.01, with no significant differences
between the two viruses following Vero cell passages P4 and P10.
Also for both viruses, a slight increase in virus titers was found for
MRC-5 cell passage P10 compared to P4. Titers of both viruses
following Vero cell passages were between 17-fold to 25-fold
higher compared to titers measured after MRC-5 cell passages.
DEN-4 2A and DEN-4 2AD30 virus neurovirulence
following Vero and MRC-5 cells passages
To further evaluate DEN-4 2A and DEN-4 2AD30 neurovir-
ulence following Vero and MRC-5 cell passages, we intracranially
inoculated a group of newborn ICR mice with 10
4 PFU/30 mlo f
either virus stock. Survival data are shown in Figures 3A and 3B.
As shown, higher neurovirulence was observed in both the DEN-4
2A and the DEN-4 2AD30 viruses following passages P2, P4 and
P10 in Vero cells. In contrast, a significant less extent of mouse
neurovirulence was observed in the DEN-4 2A virus following
passage P2, P4, and P10 in MRC-5 cells. The DEN-4 2AD30
viruses passaged in MRC-5 cells did not show any neurovirulence.
Overall, neurovirulence for DEN-4 2A and DEN-4 2AD30 viruses
increased significantly following passages in Vero cells compared
to passages in MRC-5 cells.
DEN-induced mouse hemorrhage pathogenicity
following DEN-4 2A and DEN-4 2AD30 passages in Vero
and MRC-5 cells
We examined DEN-induced hemorrhaging in an immunocom-
petent mouse model [36,37]. C57BL/6 mice were injected
intradermally with DEN-4 2A or DEN-4 2AD30 viruses that
had been passaged in Vero or MRC-5 cells (P4 and P10). Data
from two independent experiments are shown in Table 3. DEN-
induced hemorrhaging was observed in epidermal and subcuta-
neous tissues at day 3 (Fig. 4). Between Vero cell passages P4 and
P10, average hemorrhage rate (6 S.D.) increased from 58611%
to 100% for the DEN-4 2A virus, and from 0% to 4567% for the
DEN-4 2AD30 virus. In contrast, between MRC-5 cell passages
P4 and P10, the average rate changed from 58611% to 33646%
for DEN-4 2A, and 17623% to 2363% for DEN-4 2AD30. In
other words, more severe DEN-induced hemorrhaging occurred
following DEN-4 2A and DEN-4 2AD30 passages in Vero cells
compared to the same passages in MRC-5 cells.
Table 2. Nucleotide (nt) and amino acid (aa) changes in NS2B-NS3 fragments of plaque-purified Vero- and MRC-5-passaged DNA-
derived DEN-4 2A and DEN-4 2AD30 virus clones.
Virus Cell Passage Number Virus Gene Segment Mutation
Frequency
Plaque-purified
Clone Number
Nucleotide
Position
Amino Acid
Position
DEN-4 2A Vero 4 NS3 2/10 3, 8 G 5776 C R 418 T
DEN-4 2A Vero 10 NS2B 5/10 2, 4, 5, 6, 9 G 4338 C G 69 R
DEN-4 2A Vero 10 NS2B 10/10 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 G 4367 T Q 78 H
DEN-4 2A Vero 10 NS2B 7/10 1, 3, 4, 7, 8, 9, 10 G 4455 C G 108 R
DEN-4 2A Vero 10 NS2B 3/10 2, 5, 6 G 4470 A A 113 T
DEN-4 2A Vero 10 NS3 5/10 3, 4, 5, 8, 10 G 5776 C R 418 T
DEN-4 2AD30 Vero 10 NS2B 10/10 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 C 4224 A P 31 T
DEN-4 2AD30 Vero 10 NS2B 10/10 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 G 4295 C E 54 D
DEN-4 2AD30 Vero 10 NS2B 3/10 1, 5, 8 A 4344 C S 71 R
DEN-4 2AD30 Vero 10 NS2B 10/10 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 G 4356 C E 75 Q
DEN-4 2AD30 Vero 10 NS2B 6/10 1, 2, 3, 5, 8, 9 G 4359 A V 76 M
doi:10.1371/journal.pone.0025800.t002
Figure 2. Virus growth properties in Vero and MRC-5 cells. Shown are the highest virus titers following passages P4 and P10 in Vero and MRC-
5 cells for (A) DEN-4 2A (B) DEN-4 2AD30.
doi:10.1371/journal.pone.0025800.g002
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4 2A mutant of E-T138P, E-G328S, E-Q438H, E-V463L, NS2B-
G69R, NS2B-Q78H, NS2B-G108R, or NS2B-A113T
Target mutagenesis by using DEN-4 2A infectious clone was
finally conducted to examine the mutations of E-T138P, E-G328S,
E-Q438H, E-V463L, NS2B-G69R, NS2B-Q78H, NS2B-G108R, and
NS2B-A113T on DEN-induced mouse hemorrhage pathogenicity.
Data are shown in Table 4 and Table 5 for E and NS2B mutants,
respectively. DEN-induced hemorrhaging by DEN-4 2A mutant
viruses was observed in epidermal and subcutaneous tissues at day
3 compared to wild type DEN-4 2A virus. Recombinant DEN-4
2A with single mutations at E-Q438H, E-V463L, NS2B-Q78H, and
NS2B-A113T had increased severity of DEN-induced mouse
hemorrhaging as compared to the wild-type DEN-4 2A viruses.
Collectively, our data suggest that the E-Q438H, E V463L, NS2B-
Q78H and NS2B-A113T mutations, which were acquired from
DEN-4 2A virus passaged in Vero cells, enhanced hemorrhaging
in the immunocompetent mouse model, irrespective of other E
Figure 3. Neurovirulence assay results for newborn mice injected with cloned DNA-derived DEN-4 2A and DEN-4 2AD30 virus
strains following passages in Vero and MRC-5 cells. Shown are survival rates for newborn mice infected with (A) DEN-4 2A and (B) DEN-4
2AD30.
doi:10.1371/journal.pone.0025800.g003
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cells and MRC-5 cells.
Virus Strain Cell Line Passage Number Mouse No. DEN-induced hemorrhaging in mice
Skin Subcutaneous
% Hemorrhage
Development
Average % of Mice with
Hemorrhage Development
DEN-4 2A Vero 4 1-1 22 66% 58611%
41 - 2 ++ +
41 - 3 +++ ++
42 - 1 22 50%
42 - 2 22
42 - 3 + 2
42 - 4 + 2
10 1-1 ++ + 100% 10060%
10 1-2 ++ +
10 2-1 2 ++ 100%
10 2-2 ++ +
10 2-3 + 2
10 2-4 2 +
10 2-5 ++ +
MRC-5 4 1-1 22 66% 58611%
41 - 2 ++ +
41 - 3 ++ +
42 - 1 + 2 50%
42 - 2 22
42 - 3 22
42 - 4 + 2
Virus Strain Cell Line Passage Number Mouse No. DEN-induced hemorrhaging in mice
Skin Subcutaneous
% Hemorrhage
Development
Average % of Mice with
Hemorrhage Development
DEN-4 2A MRC-5 10 1-1 2 ++ 66% 33646%
10 1-2 2 ++
10 1-3 22
10 2-1 22 0%
10 2-2 22
DEN-4
2AD30
Vero 4 1-1 22 0% 060%
41 - 2 22
41 - 3 22
42 - 1 22 0%
42 - 2 22
42 - 3 22
42 - 4 22
10 1-1 + 2 40% 4567%
10 1-2 22
10 1-3 22
10 1-4 ++
10 1-5 22
10 2-1 2 + 50%
10 2-2 22
10 2-3 22
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Vero cells.
Discussion
Since live-attenuated vaccines require limited seed virus passage
levels to prevent unsafe reversion, seed viruses must maintain their
genetic stability during cell passages as part of the vaccine
manufacturing process. Based on 74% of DEN genome sequenc-
ing (including all C-prM-E structure protein genes and full-length
NS2B, NS3, NS4B, and NS5 genes), our results indicate stronger
genetic stability for the infectious cDNA clone-derived viruses
DEN-4 2A or DEN-4 2AD30 following passages in MRC-5 cells
compared to passages in Vero cells. This corresponds to
significantly lower DENpol error rates when the DEN virus is
used for genome replication.
Pugachev et al.’s (2004) method for analyzing plaque-purified
clones following different cell passages provides a systematic means
for qualitatively and quantitatively examining the genetic stability
of vaccine viruses [38]. In an earlier study we examined DEN-4
2A virus mutations following Vero and MRC-5 cell passages by
sequencing multiple clones of DNA fragments synthesized from
DEN-4 2A RNA by RT-PCR [34]. This approach may not
accurately identify viable viruses with identical mutations by
sequencing multiple virus stock clones, but we found that plaque
purification supports the selection of viable mutant viruses for
sequencing multiple virus clones. We found that the number of
mutations detected by plaque-purified clone virus sequencing was
generally larger than the number detected by sequencing multiple
virus clones. In our previous study, the sequencing of multiple
DEN-4 2A virus clones supported the identification of mutations
occurring at E-G104C (70%), E-F108I (60%), E-G427R (20%), E-
V439F (10%), and E-V463L (10%) following passage P3 in Vero
cells [34]. In the present study, the sequencing of 10 plaque-
purified DEN-4 2A virus clones during passage P4 (equivalent to
P3 in our earlier work) in Vero cells resulted in the detection of
mutations at C-F37L (20%), E-R99K (40%), E-T138P (20%), E-
G427R (30%), E-V439F (10%), and E-V463L (30%). The differences
may be due to the low sensitivity associated with sequencing
multiple clones compared to mutations detected by sequencing
plaque-purified clones.
Differences in nucleic acid mutations detected after DEN-4 2A
and DEN-4 2AD30 passages P4 and P10 in Vero and MRC-5 cells
are shown in Tables 1 and 2. In our genetic stability analyses we
did not include mutations induced by SP6 RNA polymerase when
synthesizing RNA transcripts in vitro, or early stage mutations
from passages P1, P2, and P3. In a separate study we used direct
sequencing to analyze the full-length DEN genomes of (a) the
DEN-4 2A virus following passage P1 in Vero cells and (b) the
DEN-2AD30 virus following passage P2 in Vero cells; we observed
6 nucleotide changes in the former and 16 in the latter (data not
shown). If these mutations were mistakes resulting from the
introduction of SP6 RNA polymerase during a single round of
DNA-dependent RNA synthesis, then our error rates would have
been 5.63610
24 per nucleotide copied for the DEN-4 2A
infectious clone (6 misincorporations per genomic RNA molecule
with a length of 10,649 nucleotides), and 1.5610
23 per copied
nucleotide for the DEN-4 2AD30 infectious clone (16 misincor-
porations per genomic RNA molecule with a length of 10,619
nucleotides). These results are comparable to the SP6 RNA
polymerase error rate of 1.34610
24 per nucleotide reported by
Pugachev et al. [38]. To calculate estimated error rates for DEN
virus RNA polymerase in C-prM-E, NS2B-NS3 and NS4B-NS5
genes, we divided the number of DENpol mistakes by the number
of sequenced full genome equivalents, the estimated number of
RNA synthesis rounds during one plaque formation cycle, and the
Virus Strain Cell Line Passage Number Mouse No. DEN-induced hemorrhaging in mice
Skin Subcutaneous
% Hemorrhage
Development
Average % of Mice with
Hemorrhage Development
DEN-4
2AD30
MRC-5 4 1-1 22 33% 17623%
41 - 2 + 2
41 - 3 22
42 - 1 22 0%
42 - 2 22
42 - 3 22
42 - 4 22
10 1-1 22 20% 2363%
10 1-2 + 2
10 1-3 22
10 1-4 22
10 1-5 22
10 2-1 22 25%
10 2-2 + 2
10 2-3 22
10 2-4 22
Rates represent hemorrhage percentage in each independent experiment. A three-level bleeding scoring low (‘‘+’’), medium (‘‘++’’), high (‘‘+++’’), and no bleeding (‘‘2‘‘)
was used to indicate the severity of hemorrhaging between different experimental cases.
doi:10.1371/journal.pone.0025800.t003
Table 3. Cont.
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in Table S1, we identified 37 and 28 DENpol mistakes in the
DEN-4 2A virus during Vero cell passages P4 and P10 for the C-
prM-E and NS2B-NS3 genes, respectively; in contrast, only 2 C-
prM-E and 0 NS2B-NS3 mistakes were found following MRC-5
cell passages P4 and P10. The estimated C-prM-E gene error rates
following DEN-4 2A Vero and MRC-5 cell passages were 1.05–
1.16610
26 and 6.29–7.30610
28 per copied nucleotide per
genomic RNA molecule (10,649 nt). Compared to MRC-5 cell
passages, the estimated C-prM-E gene error rate in the DEN-4 2A
virus increased 17.5-fold following Vero cell passages. Estimated
C-prM-E gene error rates for the DEN-4 2AD30 virus following
Vero and MRC-5 passages were 6.57–7.26610
27 and 0 per
copied nucleotide, respectively. Regarding NS2B-NS3 gene
mutations during Vero cell passages, estimated error rates were
7.98–8.81610
27 and 1.11–1.23610
26 per copied nucleotide for
DEN-4 2A and DEN-4 2AD30 viruses, respectively. In all cases,
DENpol error rates for both viruses were significantly higher
following Vero cell passages compared to MRC-5 cell passages.
However, we can not rule out other cellular factors interacted with
viral factors and play a role in the selection of specific mutations.
The replication kinetics of DEN-4 2A and DEN-4 2AD30
viruses have been investigated in Vero and MRC-5 cells which are
now being used to develop several human vaccines [18]. The viral
yields of DEN-4 2A and DEN-4 2AD30 viruses produced in
MRC-5 cells on microcarriers (at P4 or P10) were approximately
10-fold lower compared to those in Vero cells with more amino
acid mutations during the , respectively (Table 2). One research
team that has introduced mutations into the 39-NTR of DEN
(using the DEN-4 2AD30 infectious cDNA clone for purposes of
attenuating vaccine candidates) describes the DEN-4 2AD30
cDNA clone as balancing between attenuation and immunoge-
nicity in a non-human primate model [11,15,21,35,39]. We used
newborn ICR mice to evaluate the attenuation of neurovirulence
of DEN-4 2A and DEN-4 2AD30 viruses following passages P2,
P4, and P10 in Vero or MRC-5 cells. In a previous study, Huang
et al. evaluated the neurovirulence of DEN-4 1036 virus (collected
from an Indonesian child with dengue fever) by injecting 10
4 PFU
of the virus intracranially into newborn ICR mice; average
survival time was 8.660.6 days [26]. Average survival times for
newborn ICR mice intracranially injected with passaged DEN-4
2A and DEN-4 2AD30 viruses were longer than that for DEN-4
1036-treated mice, indicating less neurovirulence for the DEN-4
2A and DEN-4 2AD30 viruses. Neurovirulence for DEN-4 2A and
DEN-4 2AD30 viruses increased significantly following passages in
Vero cells compared to passages in MRC-5 cells.
In addition to being the major determinant of tropism and
virulence, the DEN virus E protein is the primary target of
Figure 4. Hemorrhage assessment of immunocompetent C57BL/6 mice. DEN-4 2A viruses following passages in (A) Vero and (B) MRC-5 cells
and DEN-4 2AD30 viruses following passages in (C) Vero and (D) MRC-5 cells were intradermally injected with 4610
7 PFU DENV (in 0.4 ml) at four
sites on the upper back. To determine degree of hemorrhaging, mice were sacrificed at 3 days post-inoculation, and subcutaneous tissues in the
back, abdomen, axillary areas, and thorax were exposed.
doi:10.1371/journal.pone.0025800.g004
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DEN-4 infectious clone viruses resulted in mutations at residues E-
R99K, E-T138P, E-G328S, E-G427R, E-Q438H, and E-V463Li nt h e
DEN-4 2A virus, and residues E-R410G, E-V443A, E-T468K, and
E-T491P in the DEN-4 2AD30 virus. In contrast, the P10 MRC-5
cell passages produced mutations at residues E-E345K, E-N362K,
and E-Q438H of the DEN-4 2A virus only—no DEN-4 2AD30
virus mutations were observed. Our results using target mutagen-
esis at E-Q438H and E-V463L to generate mutant viruses had
increased severity of DEN-induced mouse hemorrhaging (Table 4).
The E-Q438H amino acid mutation, which is located in the second
helix domain (E-H2) of the E protein stem region, was detected
following passage P10 only (100% mutation frequency). The E-
V463L mutation in the DEN-4 2A virus resulting from the P10
Vero cell passage is located in the N-terminus of the first (E-T1)
helix of the E protein transmembrane domain (TMD), which also
contains an endoplasmic reticulum retention signal. Our results
indicate more severe DEN-induced hemorrhages in mice following
DEN-4 2A and DEN-4 2AD30 passages in Vero cells, but not
following passages in MRC-5 cells.
A cluster of NS2B mutations also appeared during Vero cell
passage P10 in both DEN-4 2A and DEN-4 2AD30 viruses
(Tables 3 and 4). Flavivirus-specified protease activity for cytosol
cleavages at dibasic sites in polyproteins requires both NS2B and
NS3 [40,41]. The dual-component NS2B-NS3 protease executes
most of this segmentation at the NS2A/NS2B, NS2B/NS3, NS3/
NS4A, and NS4B/NS5 junctions. The cleavage mediated by
NS2B and NS3 is an essential step in viral replication. The NS3 N-
terminus encodes the enzymatic core, while a hydrophilic core
within NS2B (NS2Bc) provides an essential cofactor function
[42,43]. NS2Bc unravels to increase the basal proteolytic activity
of NS3 protease by 3,300-fold to 7,600-fold [44]. It was reported
that the C-terminal region of NS2Bc (residues 67 to 95) plays a
substrate-binding role in the proteolytic activity of NS3 protease
[45]. The NS2B-G69R and NS2B-Q78H mutations from DEN-4
2A passages in Vero cells and the NS2B-S71R, NS2B-E75Q, and
NS2B-V76M mutations from DEN-2A D30 passages in Vero cells
are located in the C-terminal region of NS2Bc. Target
mutagenesis on NS2B mutant viruses also indicated that single
point mutation of NS2B-Q78H and NS2B-A113T imperatively
increased mouse hemorrhaging severity. As the NS2B is a cofactor
for NS3 protease activation, the mutation of NS2B-Q78Hi s
located in a hydrophobic stretch of NS2B residues Gly
70-Glu
81,
which located in a hydrophilic cofactor domain as previously
Table 4. Hemorrhage assessment in immunocompetent C57BL/6 mice of DEN-4 2A E gene single amino acid mutant viruses.
Virus Strain
Substitution
Mutation
Viruses Mouse No. Severity of Hemorrhage % of Hemorrhage Development
Skin Subcutaneous
DEN-4 2A Wild type 1-1 + 2 20%
1-2 22
1-3 22
1-4 22
1-5 22
E-T138P2 - 1 ++ 2 40%
2-2 + 2
2-3 22
2-4 22
2-5 22
E-G328S3 - 1 22 20%
3-2 22
3-3 22
3-4 22
3-5 + 2
E-Q438H4 - 1 22 60%
4-2 2 +
4-3 22
4-4 ++
4-5 ++ 2
E-V463L5 - 1 22 80%
5-2 +++ 2
5-3 ++
5-4 + 2
5-5 ++ 2
Rates represent hemorrhage percentage in each independent experiment. A three-level bleeding scoring low (‘‘+’’), medium (‘‘++’’), high (‘‘+++’’), and no bleeding (‘‘2‘‘)
was used to indicate the severity of hemorrhaging between different experimental cases.
doi:10.1371/journal.pone.0025800.t004
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from amide group to imidazole group, and the electricity change
from no charge to positive charge of NS2B-Q78H may change the
NS2B cofactor efficiency to affect the NS3 protease activity [47].
The NS2B-Q78H and NS2B-A113T had the same virus replication
patterns in human microvascular endothelial (HMEC-1) cells with
the wild type virus, and these mutations had no influence on
affecting the cell survival signaling or introduce cell death pathway
in the infected cells which then leads to hemorrhaging phenotypes
(data not shown). The relationship of the NS2B/NS3 protease
interactions contributed to DEN-induced hemorrhaging in mice is
still unknown. The virus-host cell mechanism underlying DHF is
not fully understood, and the relationship between amino acid
mutations acquired during Vero cell passage and enhanced DEN-
induced hemorrhages in mice may be important for understanding
DHF pathogenesis, as well as for the development of live–
attenuated dengue vaccines.
Materials and Methods
Cells and Media
Vero, Vero E6, and MRC-5 cells were obtained from the
Bioresource Collection and Research Center (BCRC) of the Food
Industrial Research and Development Institute, Hsinchu, Taiwan.
Vero cells (African green monkey kidney cells) were derived from
ATCC CCL-81 (BCRC number: 60013). Vero E6 cells (BCRC
number: 60476; ATCC CRL-1586), derived from VERO 76 cells
(ATCC CRL-1587), were cloned by the microtiter plate dilution
method. MRC-5 cells (human embryonal lung fibroblasts) were
derived from ATCC CCL-171 (BCRC number: 60023). Vero,
Vero E6, and MRC-5 cells were grown in Dulbecco’s Modified
Essential Medium (DMEM) (Invitrogen) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and 100 U/ml of
penicillin G sodium-streptomycin (Invitrogen). Vero and MRC-5
cells were also cultured in M-VSFM serum free medium (Biogrow)
with 100 U/ml of penicillin G sodium-streptomycin. No prior
adaptation in reduced serum concentrations was required for the
serum free cultures. Trypsin inhibitor (GIBCO) was used at 0.25%
for cell detachment to protect cell damage by trypsin treatment
under serum-free conditions.
Viruses
Stock viruses were prepared from the supernatants of infected
C6/36 cells grown in Hank’s MEM medium (GIBCO) plus
supplements. Plasmids of DEN-4 2A and its 39NCR deletion
Table 5. Hemorrhage assessment in immunocompetent C57BL/6 mice of DEN-4 2A NS2B gene single amino acid mutant viruses.
Virus Strain
Substitution
Mutation
Viruses Mouse No. Severity of Hemorrhage % of Hemorrhage Development
Skin Subcutaneous
DEN-4 2A Wild type 1-1 22 40%
1-2 + 2
1-3 + 2
1-4 22
1-5 22
NS2B-G69R2 - 1 22 20%
2-2 ++ 2
2-3 22
2-4 22
2-5 22
NS2B-Q78H3 - 1 22 60%
3-2 ++ +
3-3 ++
3-4 2 ++
3-5 22
NS2B-G108R4 - 1 22 0%
4-2 22
4-3 22
4-4 22
4-5 22
NS2B-A113T5 - 1 + 2 100%
5-2 ++ ++
5-3 ++ ++
5-4 ++
5-5 ++
Rates represent hemorrhage percentage in each independent experiment. A three-level bleeding scoring low (‘‘+’’), medium (‘‘++’’), high (‘‘+++’’), and no bleeding (‘‘2’’)
was used to indicate the severity of hemorrhaging between different experimental cases.
doi:10.1371/journal.pone.0025800.t005
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Plasmids were linearized by cleavage with the Kpn I restriction
enzyme and added to a transcription reaction mixture (Promega)
containing m
7G(59)ppp(59)G (Merck) for a cap addition at the
RNA 59 end. After incubation at 37uC for 1.5 h, the RNA product
was purified with TRIzol reagent (Invitrogen) according to the
manufacturer’s instructions. Prior to RNA transfection, subcon-
fluent Vero cells and MRC-5 cells in 6-well plates were rinsed
once with serum-free medium and covered with 0.3 ml of Opti-
MEM medium (Invitrogen) per well. The transfection mixture was
prepared by adding 6 ml of DMRIE-C reagent (Invitrogen) to 1 ml
of Opti-MEM medium prior to mixing with 10 mg of the RNA
product. This mixture was added directly to the cell monolayer.
After 18 h of incubation at 37uC, either DMEM+10% FBS or M-
VSFM medium was added to each well. Culture supernatants
were collected 8 days post-transfection. All virus stocks were stored
at 280uC until further analysis.
Virus titers were determined by plaque assays of a Vero E6 cell
line. To prepare high-DENV titers (up to 10
9 plaque-forming
units/ml [PFU/ml]), virus supernatant was concentrated by
centrifugation with a Centriplus device (10-kDa cutoff) (Amicon;
Millipore). To confirm a homogenous virus population, biological
clones of passage regimens were generated via single rounds of
plaque purification in Vero or MRC-5 cells. Medium 199 (Gibco)
containing 3% FBS was used for plaque purification in six-well
culture plates (agarose overlays with neutral red staining). Agarose
plugs were carefully removed to avoid disturbing the monolayers.
Each selected clone was propagated once in Vero or MRC-5 cells
to confirm viability.
Microcarrier cultures
Cytodex 1 microcarriers (Amersham Biosciences) were prepared
according to the manufacturer’s instructions. Briefly, microcarriers
were immersed in PBS for at least 3 h and autoclaved for 15 min
before each experiment. Autoclaved microcarriers were washed
twice with culture medium. Bellco spinner flasks were used in the
experiments at a working volume of 50 ml. Flasks were stirred at
60 rpm and incubated with 5% CO2 at 37uC. Cells were detached
from tissue culture flasks using trypsin-EDTA, and transferred to
flasks containing 2 g/l Cytodex 1 microcarriers. Initial cell
densities were 3610
5 cells/ml in serum-containing cultures, and
6610
5 cells/ml in serum-free cultures. Cell cultures were infected
3 days post-inoculation; 70% of the medium was replaced with
fresh medium containing virus inoculum. Inoculation continued
without further medium replacement or supplement addition.
Virus titers were determined after each passage, with the
subsequent culture infected at 0.01 MOI. Microcarrier cultures
were used for the P4 to P10 passages from which we gathered
mutation data.
Cell density and virus titer determination
Numbers of cells attached to microcarriers were determined by
nuclei staining. Briefly, a 1 ml sample of microcarrier culture was
centrifuged at 200 g for 5 min to remove supernatant. Pellets were
treated with 1 ml 0.1 M citric acid containing 0.1% (w/v) crystal
violet and incubated at 37uC for 1 h. Released nuclei were
counted in a hemacytometer. Virus titer was determined by 10-
fold serial dilutions of culture supernatant in duplicate Vero-E6
cell monolayer infections in 6-well plates. After incubation for 1 h
at 37uC, 4 ml of medium containing 16 EMEM (Invitrogen),
1.1% methylcellulose, and 100 U/ml of penicillin G sodium-
streptomycin were added to each well. Virus plaques were stained
with 1% crystal violet dye 6 days following incubation. Infectivity
titers were determined in PFU/ml.
Plaque purification
Monolayer Vero cells individually infected with tenfold serial
dilutions of infectious clone cDNA-derived DEN-4 2A-Vero-P4,
DEN-4 2A-Vero-P10, DEN-4 2A-MRC-5-P4, DEN-4 2A-MRC-
5-P10, DEN-4 2AD30-Vero-P4, DEN-4 2AD30-Vero-P10, DEN-
42 A D30-MRC-5-P4, and DEN-4 2AD30-MRC-5-P10 harvested
from passaged cell lines were cultured in 4 ml of Eagle MEM
containing 2.5% low-melting agar. Ten variant plaques derived
from each sample were collected from monolayer Vero cells 7 days
post-infection. At 5 days post-infection, cells were dyed with Eagle
MEM (2 ml) containing 2.5% low-melting agar and 16 neutral
red solution. These samples were used to infect Vero and MRC-5
cells. Amplified plaque-purified clones were used to sequence and
analyze mutation sites.
Plaque-purified clone sequencing
Three DNA fragments were synthesized from DEN-4 RNA by
RT-PCR using PlatinumH Pfx DNA polymerase and three forward
and reverse primer pairs: (i) W01F/W02R, (ii) W16F/W30R, and
(iii) W20F/W08R. The DNA products were purified using a Gel/
PCR DNA fragment extraction kit (Geneaid, Taiwan). The
nucleotide sequences of each fragment were determined by
Mission Biotech Inc., Taipei, Taiwan. Lasergene software (v.
6.0) was used to align sequences in the W01F/W02R (2,612-bp),
W16F/W30R (3,009-bp), and W20F/W08R regions (4,283-bp) to
generate a consensus sequence for each fragment.
DEN genomic mutation sequencing following Vero and
MRC-5 cell passages
DEN-4 infectious clone-derived viruses were generated by the
transfection of in vitro RNA transcripts synthesized using SP6
RNA polymerase with two infectious full-length cDNA clones of
DEN-4 2A and DEN-4 2AD30 passaged in Vero and MRC-5
cells. Ten consecutive passages (P1–P10) were investigated to
determine the genetic stability of viruses propagated by the two
cell types. To analyze genetic mutations that occurred during cell
passages, ten plaque-purified clones collected from virus stocks
after passages P4 and P10 were subjected to the genetic
sequencing of three DEN genomic fragments (C-prM-E, NS2B-
NS3 and NS4B-NS5), based on the rationale that in a previous
study most mutations occurred in these regions [34]. As described
by Pugachev et al. [38] for four chimeric yellow fever-DEN virus
vaccine candidates, it is possible to determine the RNA
polymerase fidelity of two infectious DEN-4 viruses propagated
in Vero and MRC-5 cells.
Estimated dengue virus RNA polymerase error rates
Estimated error rates for DEN virus RNA polymerase in C-
prM-E, NS2B-NS3, and NS4B-NS5 genes were calculated by
dividing the number of DENpol mistakes by the number of
sequenced full genome equivalents, the estimated number of
rounds of RNA synthesis during one plaque formation, and the
number of plaque purification steps for each clone, as previously
described [38]. The numbers of sequenced full genome equivalents
to the three genomic fragments were 2.2 kb for C-prM-E, 2.2 kb
for NS2B-NS3, and 3.4 kb for NS4B-NS5. As DEN4-2A and
DEN4-2AD30 virus growth reached peak titers of ,10
7 PFU/ml
in Vero cells and ,10
6 PFU/ml in MRC-5 cells, a plaque pick of
approximately 500 ml resulted in ,5610
6 infectious particles
being produced in Vero cells and ,5610
5 infectious particles
being produced in MRC-5 cells. Assuming that 100 to 1,000 times
additional RNA molecules are synthesized during flavivirus
replication [38], the estimated numbers of RNA synthesis rounds
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MRC-5 cells.
Target mutagenesis, construction of DEN-4 2A E-T138P, E-
G328S, E-Q438H, E-V463L, NS2B-G69R, NS2B-Q78H, NS2B-
G108R, and NS2B-A113T infectious cDNA clones, and
recovery of mutant viruses
The infectious clones DEN-4 2A, which contain infectious
DENV cDNA corresponding to the anti-genome of the DENV-4
vaccine candidate strain 814669, have been described elsewhere
[21]. The clone-derived virus, DEN-4 2A, exhibits the same
phenotypes as the DENV-4 vaccine candidate strain 814669 virus
and was used as wt control. Target mutagenesis generating the
mutant cDNA clones were performed by using overlapped PCR
method. To construct DEN-4 2A E-T138P infectious cDNA
clones, PCR fragments containing corresponding mutations were
amplified by two rounds of PCR reactions. The first round was
done by using primer pairs HpaI-f : 59-TGATTGGATTCAG-
GAAGGAG-39 and T138P-r: 59-ACAACCACTGGGTATT-
CAAG-39, and T138P-f: 59-CTTGAATACCCAGTGGTTGT-
39(this changed E gene amino acid no. 138 from Thr to Pro; from
ACA to CCA) and NsiI-r 59-AGTCCACTTCTGTGGCTCCA-
39 for construction of DEN-4 2A E-T138P. The second round was
done by using the same primer pairs HpaI-f : 59-TGATTG-
GATTCAGGAAGGAG-39 and NsiI-r 59-AGTCCACTTCT-
GTGGCTCCA-39. The 1,412 bp HpaI-NsiI PCR fragments were
cloned into the pJET1.2/blunt cloning vector (Fermentas Life
Sciences Corp.) for amplification. A 1,412 bp region flanked by
HpaI and NsiI restriction enzyme sites in DEN-4 2A infectious
clone was replaced with HpaI-NsiI fragment derived from
confirmed clones, which contained E-T138P mutation in DEN-4
2A infectious clones. To construct DEN-4 2A E-G328S, E-Q438H,
E-V463L, infectious cDNA clones, PCR fragments containing
corresponding mutations were amplified by two rounds of PCR
reactions. The first round was done by using primer pairs NsiI-f :
59-TTTAAGGTTCCTCATGCCAAG-39 and G328S-r: 59-
GCTCCAGCACTTTCATACTT-39, and G328S-f: 59-CAAG-
TATGAAAGTGCTGGAGC-39(this changed E gene amino acid
no. 328 from Gly to Ser; from GGT to AGT) and StuI-r 59-
CAACATGATGAGGGCTCGTA-39 for construction of DEN-4
2A E-G328S; primer pairs NsiI-f : 59-TTTAAGGTTCCTCA-
TGCCAAG-39 and Q438H-r: 59-CCAAAAACGTGGTGCACA-
GC-39, and Q438H-f: 59- GCTGTGCACCACGTTTTTGG-
39(this changed E gene amino acid no. 438 from Gln to His;
from CAG toCAC) and StuI-r 59-CAACATGATGAGGGC-
TCGTA-39 for construction of DEN-4 2A E- Q438H; primer
pairs NsiI-f : 59-TTTAAGGTTCCTCATGCCAAG-39 and
V463L-r: 59-ATCCACAACAGTAAGAACCC-39, and V463L-f:
59-GGGTTCTTACTGTTGTGGAT-39(this changed E gene
amino acid no. 463 from Val to Leu; from GTG toCTG) and
StuI-r 59-CAACATGATGAGGGCTCGTA-39 for construction of
DEN-4 2A E- V463L. The second round was done by using the
same primer pairs NsiI-f : 59-TTTAAGGTTCCTCATGCCA-
AG-39 and StuI-r 59-CAACATGATGAGGGCTCGTA-39. The
2,003 bp NsiI-StuI PCR fragments were cloned into the pJET1.2/
blunt cloning vector (Fermentas Life Sciences Corp.) for
amplification. A 1,412 bp region flanked by HpaI and NsiI
restriction enzyme sites in DEN-4 2A infectious clone was
replaced with HpaI-NsiI fragment derived from confirmed clones,
which contained E-T138P mutation in DEN-4 2A infectious clones.
To construct DEN-4 2A NS2B-G69R, NS2B-Q78H, NS2B-G108R,
and NS2B-A113T infectious cDNA clones, PCR fragments
containing corresponding mutations were amplified by two rounds
of PCR reactions. The first round was done by using primer pairs
StuI-f : 59-CACTCTTTGTGCTATCATCT-39 and G69R-r: 59-
GGCTTGAGCGTGTTATGTC -39, and G69R-f: 59-GACA-
TAACACGCTCAAGCC-39(this changed NS2B gene amino acid
no. 69 from Gly to Arg; from GGC to CGC) and BstBI-r 59-
CATTATAGTTAATCTTTTCTTTC-39 for construction of
DEN-4 2A NS2B-G69R; primer pairs StuI-f : 59-CACTCT-
TTGTGCTATCATCT-39 and Q78H-r: 59-TCTTCATCATG-
CTTCACTTC-39, and Q78H-f: 59-GAAGTGAAGCATGATG-
AAGA-39(this changed NS2B gene amino acid no. 78 from Gln to
His; fromCAG to CAT) and BstBI-r 59- CATTATAGTTAAT-
CTTTTCTTTC-39 for construction of DEN-4 2A NS2B-Q78H;
and primer pairs StuI-f : 59-CACTCTTTGTGCTATCATCT-39
and G108R -r: 59- GGGTAGAGACGTGACACTG-39, and
G108R -f: 59-CAGTGTCACGTCTCTACCC-39(this changed
NS2B gene amino acid no. 108 from Gly to Arg; fromGGT
toCGT) and BstBI-r 59- CATTATAGTTAATCTTTTCTTTC-
39 for construction of DEN-4 2A NS2B- G108R; and primer pairs
StuI-f : 59-CACTCTTTGTGCTATCATCT-39 and A113T-r: 59-
TGGAATTGTCAAGGGGTAG-39, and A113T-f: 59-CTACC-
CCTTGACAATTCCA-39(this changed NS2B gene amino acid
no. 113 from Ala to Thr; fromGCA toACA) and BstBI-r 59-
CATTATAGTTAATCTTTTCTTTC-39 for construction of
DEN-4 2A NS2B- A113T. The infectious cDNA clones of parental
virus DEN-4 2A was used as the template in PCR reactions. The
second round was done by using the same primer pairs StuI-f : 59-
CACTCTTTGTGCTATCATCT-39 and BstBI-r 59- CATTA-
TAGTTAATCTTTTCTTTC-39. The 1,503 bp StuI- BstBI PCR
fragments were cloned into the pJET1.2/blunt cloning vector
(Fermentas Life Sciences Corp.) for amplification. To introduce
changes at NS2B protein, a 1,453 bp region flanked by StuI and
BstBI restriction enzyme sites in DEN-4 2A infectious clone was
replaced with StuI-BstBI fragments derived from confirmed clones,
which contained NS2B-G69R, NS2B-Q78H, NS2B-G108R, or
NS2B-A113T mutations in DEN-4 2A infectious clones. The
mutant DEN-4 2A infectious clones were confirmed by sequencing
analysis. The mutant plasmids were first linearized by cleavage
with restriction enzyme KpnI and then added to a transcription
reaction mixture, transcribed using SP6 RNA polymerase within
the RiboMAX
TM large scale RNA production system (Promega
Corp.). Full-length RNA transcripts were further capped with
m
7G(59)ppp(59)G at the RNA 59-end by using Script Cap Capping
enzyme (EPICENTRE Corp.). After incubation at 37uC for
1 hour, the RNA product was purified with TRIzol LS reagent
(Invitrogen Corp.) according to manufacturer’s instructions. Prior
to RNA transfection, subconfluent Vero cells and MRC-5 cells in
a 6-well plate were rinsed once with serum-free medium and then
covered with 0.3 ml of DMEM medium per well. The transfection
mixture was prepared by adding 4 ml of DMRIE-C reagent
(Invitrogen) to 1 ml of DMEM, then mixing with 10 mg of the
RNA product. The transfection mixture was added directly to
cell monolayer. After 18 hours incubation at 37uC, either
DMEM+10% FBS or M-VSFM medium were added to the well.
Eight days after transfection, culture supernatants were collected.
All virus stocks were stored at 280uC freezer for further analysis.
The virus titer was then determined by plaque assay on a Vero-E6
cell line. To prepare high titers of DENV, virus supernatant was
concentrated with a Centriplus device (10-kDa cutoff) (Amicon;
Millipore) by centrifugation before the plaque assay. The virus
titer could reach 10
9 PFU/ml after concentration. The inoculum
was prepared by diluting virus stocks in Hank’s balanced salt
solution (Invitrogen) containing 0.4% bovine serum albumin
fraction V (Gibco) (HBSS-0.4% BSA fraction V) immediately
before inoculation.
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All mice were housed at the National Tsing Hua University
barrier facility, and cared for according to protocols approved by
the university’s Institutional Animal Care and Use Committee
(Permit Number: 09734). We performed each neurovirulence and
in vivo hemorrhage experiment at least two times.
Neurovirulence in suckling mice
Litters of newborn (less than 24 hrs) outbred white ICR mice
(BioLASCO Taiwan Co., Ltd) were inoculated intracranially with
30 ml of mock diluent or diluent containing 10
4 PFU of DEN-4
2A-Vero-P4, DEN-4 2A-MRC-5-P4, DEN-4 2A -Vero-P10,
DEN-4 2A-MRC-5-P10, DEN-4 2AD30-Vero-P4, DEN-4
2AD30-MRC-5-P4, DEN-4 2AD30-Vero-P10, or DEN-4 2AD30-
MRC-5-P10 as described previously [26,48]. HBSS-0.4% BSA
fraction V (GIBCO) was used as a diluent. Each group consisted of
at least 10 newborn mice per treatment. Mice were observed for
18 days. We collected data on moribund status, paralysis, and
mortality.
Dengue virus-induced hemorrhaging mouse model
Immunocompetent C57BL/6 mice were obtained from the
Jackson Laboratory (Bar Harbor, ME) and bred at the Laboratory
Animal Center of the National Taiwan University College of
Medicine. All mice were housed in sterile cages fitted with filtered
cage tops and fed sterilized food and water. At 4–5 weeks of age,
mice were intradermally inoculated with 4610
7 PFU DENV (in
0.4 ml of PBS) at four sites on the upper back. Control mice were
given PBS and culture medium in the same manner. Mice were
sacrificed 3 days post-infection. Subcutaneous tissues in the back,
abdomen, and axillary areas and thorax were exposed to observe
hemorrhaging.
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